Anavex Life Sciences Corp (AVXL)

[sokol]

If Blarcamesine works well with APOE3 patients, Anavex will focus on those APOE3 patients. This too would be highly significant in seeking approval in Asia. APOE3 is the most common among all human populations. Interestingly, its frequency varies throughout the world. Most interestingly its frequency in Asia seems to be the highest - 85%. ! APOE4 is relatively high in Australia, but highest in Central Africa.

“The world-wide frequency of human APOE alleles varies considerably (Figure 1). APOE3 is the most common among all human populations and its frequency ranges from 85% (Asia) to 69% (Africa) (Singh et al., 2006). APOE4 allele frequency varies considerably in native populations of Central Africa (40%), Oceania (37%), and Australia (26%) (Corbo and Scacchi, 1999). The distribution across Europe and Asia follows an apparent gradient from north to south, with low APOE4 allele frequencies in the Mediterranean or South China and higher frequencies in northern regions (up to 25%) (Egert et al., 2012). APOE2 is the least common allele with a global prevalence of 7.3% and is absent in many indigenous people without any clear regional pattern”.

https://www.frontiersin.org/articles/10.3389/fnins.2021.630502/full